JWCA has advised esperion on capital market transactions with OVER $700 MILLION in transaction Value

December 2024: JWCA acts as financial advisor and sole placement agent to Esperion Therapeutics on its $150 million secured term loan and $100 million convertible financing to refinance 79% of its existing convertible

June 2024: JWCA acted as financial advisor to Esperion on the $305 million monetization of its EU royalty on bempedoic acid and repurchase of existing revenue interests

November 2020: JWCA advises Esperion on its inaugural $250 million convertible bond, capped call, and prepaid forward transaction